Cholinergic Urticaria, an Effective and Safe “Off Label” Use of Dupilumab: A Case Report with Literature Review

References

• Fukunaga A, Washio K, Hatakeyama M, et al. Cholinergic urticaria: epidemiology, physiopathology, new categorization, and management. Clin Auton Res. 2018;28(1):103–113. doi:10.1007/s10286-017-0418-6
   PubMed Web of Science ®Google Scholar
• Hirschmann JV, Lawlor F, English JS, Louback JB, Winkelmann RK, Greaves MW. Cholinergic urticaria. A clinical and histologic study. Arch Dermatol. 1987;123(4):462–467. doi:10.1001/archderm.1987.01660280064024
   PubMedGoogle Scholar
• Moore-Robinson M, Warin RP. Some clinical aspects of cholinergic urticaria. Br J Dermatol. 1968;80(12):794–799. doi:10.1111/j.1365-2133.1968.tb11948.x
   PubMed Web of Science ®Google Scholar
• Magerl M, Borzova E, Gimenez-Arnau A, et al. The definition and diagnostic testing of physical and cholinergic urticarias–EAACI/GA2LEN/EDF/UNEV consensus panel recommendations. Allergy. 2009;64:1715–1721. doi:10.1111/j.1398-9995.2009.02177.x
   PubMed Web of Science ®Google Scholar
• Goodman B, Jariwala S. Dupilumab as a novel therapy to treat adrenergic urticaria. Ann Allergy Asthma Immunol. 2021;126(2):205–206. doi:10.1016/j.anai.2020.06.034
   PubMed Web of Science ®Google Scholar
• Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticarias - the EAACI/GA(2) LEN/EDF/UNEV con, the EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 2016;71(6):780–802. doi:10.1111/all.12884
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and managemen, t of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270–1277. doi:10.1016/j.jaci.2014.02.036
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Aberer W, Burtin B, Rihoux JP, Czarnetzki BM. Efficacy of cetirizine in cholinergic urticaria. Acta Derm Venereol. 1995;75:147–149. doi:10.2340/0001555575147149
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Munzberger C, Haustein U, et al. Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology. 1996;193:324–327. doi:10.1159/000246281
   PubMed Web of Science ®Google Scholar
• Sirufo MM, De Pietro F, Bassino EM, Ginaldi L, De Martinis M. Translational allergy and omalizumab: the pioneer. Indian J Pharma Educ Res. 2021;55(1):s259–s264. doi:10.5530/ijper.55.1s.58
   Web of Science ®Google Scholar
• Tsunemi Y, Ihn H, Saeki H, Tamaki K. Cholinergic urticaria successfully treated with scopolamine butylbromide.Int. J Dermatol. 2003;42:850.
   Web of Science ®Google Scholar
• Wong E, Eftekhari N, Greaves MW, Ward AM. Beneficial effects of danazol on symptoms and laboratory changes in cholinergic urticaria. Br J Dermatol. 1987;116:553–556. doi:10.1111/j.1365-2133.1987.tb05877.x
   PubMed Web of Science ®Google Scholar
• La Shell MS, England RW. Severe refractory cholinergic urticaria treated with danazol. J Drugs Dermatol. 2006;5:664–667.
   PubMedGoogle Scholar
• Kennes B, De Maubeuge J, Delespesse G. Treatment of chronic urticaria with a beta2-adrenergic stimulant. Clin Allergy. 1977;7:35–39. doi:10.1111/j.1365-2222.1977.tb01422.x
   PubMedGoogle Scholar
• Conway MJ. A beta-adrenergic blocker for cholinergic urticaria. Practitioner. 1982;226:940–941.
   PubMedGoogle Scholar
• Kozaru T, Fukunaga A, Taguchi K, et al. Rapid desensitization with autologous sweat in cholinergic urticaria. Allergol Int. 2011;60:277–281. doi:10.2332/allergolint.10-OA-0269
   PubMedGoogle Scholar
• Nakamizo S, Egawa G, Miyachi Y, Kabashima K. Cholinergic urticaria: pathogenesis-based categorization and its treatment options. J Eur Acad Dermatol Venereol. 2012;26:114–116. doi:10.1111/j.1468-3083.2011.04017.x
   PubMed Web of Science ®Google Scholar
• Dupixent, Summary of product characteristics, European Medicinal Agency. Available from: https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf. Accessed February 2, 2022.
   Google Scholar
• Föhr J, Herbst M, Jahn S. Therapie von Urtikaria und atopischer Dermatitis bei einer Patientin mit Dupilumab [Treatment of simultaneously occurring urticaria and atopic dermatitis with dupilumab]. Hautarzt. 2021;72(3):249–251. doi:10.1007/s00105-020-04675-3
   PubMed Web of Science ®Google Scholar
• Lee JK, Simpson RS. Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2019;7(5):1659–1661. doi:10.1016/j.jaip.2018.11.018
   PubMed Web of Science ®Google Scholar
• Maurer M, Khan DA, Elieh Ali Komi D, Kaplan AP. Biologics for the use in chronic spontaneous urticaria: when and which. J Allergy Clin Immunol Pract. 2021;9(3):1067–1078. doi:10.1016/j.jaip.2020.11.043
   PubMed Web of Science ®Google Scholar
• Errichetti E, Stinco G. Recalcitrant chronic urticaria treated with dupilumab: report of two instances refractory to H1-antihistamines, omalizumab and cyclosporine and brief literature review. Dermatol Ther. 2021;34(2). doi:10.1111/dth.14821
   Web of Science ®Google Scholar
• Solish N, Bertucci V, Dansereau A. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg. 2007;(8):908–923. doi:10.1111/j.1524-4725.2007.33192.x
   Google Scholar
• Tanaka A, Tanaka T, Suzuki H, Ishii K, Kameyoshi Y, Hide M. Semi-purification of the immunoglobulin E-sweat antigen acting on mast cells and basophils in atopic dermatitis. Exp Dermatol. 2006;15:283–290. doi:10.1111/j.0906-6705.2006.00404.x
   Google Scholar
• Shelly WB, Shelly ED, Ho AK. Cholinergic urticaria: acetylcholine-receptor-dependent immediate-type hypersensitivity reaction to copper. Lancet. 1983;321:843–846. doi:10.1016/S0140-6736(83)91386-7
   Google Scholar
• Baron B, Schreiber G, Sokolovsky M. Cholinergic urticaria, copper-induced hypersensitivity, and muscarinic receptor. Lancet. 1983;322:55. doi:10.1016/S0140-6736(83)90044-2
   Google Scholar
• Tong LJ, Balakrishnan G, Kochan JP, Kinét JP, Kaplan AP. Assessment of autoimmunity in patients with chronic urticaria. J Allergy Clin Immunol. 1997;99:461–465. doi:10.1016/S0091-6749(97)70071-X
   PubMed Web of Science ®Google Scholar
• Sawada Y, Nakamura M, Bito T, et al. Cholinergic urticaria: studies on the muscarinic cholinergic receptor M3 in anhidrotic and hypohidrotic skin. J Invest Dermatol. 2010;130:2683–2686. doi:10.1038/jid.2010.188
   PubMed Web of Science ®Google Scholar
• Blandina P, Fantozzi R, Mannaioni PF, Masini E. Characteristics of histamine release evoked by acetylcholine in isolated rat mast cells. J Physiol. 1980;301:281–293. doi:10.1113/jphysiol.1980.sp013205
   PubMed Web of Science ®Google Scholar
• Fantozzi R, Masini E, Blandina P, Mannaioni PF, Bani-Sacchi T. Release of histamine from rat mast cells by acetylcholine. Nature. 1978;273:473–474. doi:10.1038/273473a0
   PubMed Web of Science ®Google Scholar
• McLeod JJ, Baker B, Ryan JJ. Mast cell production and response to IL-4 and IL-13. Cytokine. 2015;75(1):57–61. doi:10.1016/j.cyto.2015.05.019
   PubMed Web of Science ®Google Scholar
• Xia HZ, Du Z, Craig S, et al. Effect of recombinant human IL-4 on tryptase, chymase, and Fc epsilon receptor type I expression in recombinant human stem cell factor-dependent fetal liver-derived human mast cells. J Immunol. 1997;159(6):2911–2921.
   PubMed Web of Science ®Google Scholar
• Babina M, Guhl S, Artuc M, et al. IL-4 and human skin mast cells revisited: reinforcement of a pro-allergic phenotype upon prolonged exposure. Arch Dermatol Res. 2016;308:665–670. doi:10.1007/s00403-016-1688-x
   PubMed Web of Science ®Google Scholar
• Garcovich S, Maurelli M, Gisondi P, Peris K, Yosipovitch G, Girolomoni G. Pruritus as a distinctive feature of type 2 inflammation. Vaccines (Basel). 2021;9(3):303. doi:10.3390/vaccines9030303
   PubMed Web of Science ®Google Scholar
• Kolkhir P, Altrichter S, Munoz M, Hawro T, Maurer M. New treatments for chronic urticaria. Ann Allergy Asthma Immunol. 2020;124:2–12. doi:10.1016/j.anai.2019.08.014
   PubMed Web of Science ®Google Scholar
• Hendricks AJ, Yosipovitch G, Shi VY. Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review. J Dermatolog Treat. 2021;32:19–28. doi:10.1080/09546634.2019.1689227
   PubMed Web of Science ®Google Scholar
• Cholinergic Urticaria - Efficacy of Dupilumab (CHED), Charite University, Berlin, Germany, ClinicalTrials.gov Identifier: NCT03749148. Available from: https://clinicaltrials.gov/ct2/show/NCT03749148. Accessed February 2, 2022.
   Google Scholar
• Muñoz-Bellido FJ, Moreno E, Dávila I. Dupilumab: a review of present indications and uses out of indication. J Investig Allergol Clin Immunol. 2021;32. doi:10.18176/jiaci.0682
   PubMed Web of Science ®Google Scholar